Cour RPC Sein 2016 - page 139

37- Kato, S, H Endoh, Y Masuhiro, T Kitamoto, S Uchiyama, H Sasaki, S
Masushige, et al. 1995. Activation of the estrogen receptor through
phosphorylation by mitogen-activated protein kinase. Science (New York, N.Y.)
270, n°. 5241 (Décembre 1): 1491-1494.38- Campbell, R A, P Bhat-Nakshatri, N M Patel, D Constantinidou, S Ali, et H
Nakshatri. 2001. Phosphatidylinositol 3-kinase/AKT-mediated activation of
estrogen receptor alpha: a new model for anti-estrogen resistance. The Journal
of Biological Chemistry 276, n°. 13 (Mars 30): 9817-9824. 39- Polivka J Jr, Janku F. Molecular targets for cancer therapy in the
PI3K/AKT/mTOR pathwayU. UPharmacol Ther. 2014 May ;142(2):164-75. 40- LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target
for breast cancer treatment.Oncology. 2013 ;84(1) 41- Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y,
Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs
A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF.
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as
first-line endocrine therapy in postmenopausal women with locally advanced or
metastatic breast cancer.J Clin Oncol. 2013 Jan 10 ;31(2):195-202:43-56. 42- Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G,
Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El
Kouri C, Pujade-Lauraine E.14TRandomized phase II trial of everolimus in combination
with tamoxifen in patients with hormone receptor-positive, human epidermal growth
factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase
inhibitors: a GINECO study.14T13T J Clin Oncol13T. 2012 Aug 1;30 (22):2718-24. 43- Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar
B, Morales S, de Boer R, Gendreau S, Derynck M, Lackner M, Spoerke J, Yeh R-F,
Levy G, Ng V, O'Brien C, Savage H, Xiao Y, Wilson T, Lee SC, Petrakova K,
Vallentin S, Yardley D, Ellis M, Piccart M, Perez EA, Winer E. The FERGI phase II
study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus
placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or
metastatic breast cancer. SABCS, 2014, S2-02.
19